NCT03460483Completed
Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care
Ohio Prevention and Treatment of Endometrial Cancer (OPTEC) Initiative: Universal Screening for DNA Mismatch Repair Deficiency and Personalized Cancer Treatment
Source: ClinicalTrials.gov · Last updated 3 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This clinical trial studies universal screening for deoxyribonucleic acid (DNA) mismatch repair deficiency in patients with endometrial cancer, mutations in the genes responsible for Lynch syndrome (inherited forms of endometrial cancers) and other DNA changes that could help guide treatment strategies. Universal tumor DNA sequencing may help doctors better understand how to personalize care, increase length of life, and increase quality of life in patients with endometrial cancer and their relatives.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 1001 (actual)
- First submitted
- 1 Mar 2018
- Start date
- 30 Mar 2018
- Primary completion date
- 15 Jun 2025
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Diseases
- Endometrial cancer
- NCT number
- NCT03460483
What you commit to
- Study type: Interventional
- Participants enrolled: 1001
- From 30 Mar 2018 to the primary completion date, 15 Jun 2025
- 9 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Individuals must be able to speak and read English; non-English speaking individuals will be excluded
- Individuals must be able to consent for themselves; those who are unable to consent for themselves for any reason will be excluded
- Prisoners will be specifically excluded from participation in the study
- Women who have uterine sarcomas are excluded
- Pregnant women are not eligible for the study
Who the study is looking for
- Adult women who had a hysterectomy or diagnostic biopsy proving endometrial adenocarcinoma (any stage) between 10/1/2017 and 4/30/2020, and received care at one of the participating hospitals
- Adult relatives of the EC patients found to have LS
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Summa Akron City Hospital/Cooper Cancer Center Coordinator of this site? Confirm its status | Akron | United States | Unknown status |
| Aultman Health Foundation Coordinator of this site? Confirm its status | Canton | United States | Unknown status |
| University of Cincinnati Coordinator of this site? Confirm its status | Cincinnati | United States | Unknown status |
| TriHealth Cancer Institute-Westside Coordinator of this site? Confirm its status | Cincinnati | United States | Unknown status |
| University Hospitals Cleveland Medical Center* Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
| MetroHealth Medical Center Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
| Ohio State University Comprehensive Cancer Center Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
| Ohio Health Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
| Mercy Health St. Vincent Medical Center Coordinator of this site? Confirm its status | Toledo | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.